Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Bronchoscopic lung volume reduction with valves: What should the internist know?

Khaled Alshabani, MD, Thomas R. Gildea, MD, FCCP, Michael Machuzak, MD, Joseph Cicenia, MD and Umur Hatipoğlu, MD
Cleveland Clinic Journal of Medicine May 2020, 87 (5) 278-287; DOI: https://doi.org/10.3949/ccjm.87a.19083
Khaled Alshabani
Respiratory Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R. Gildea
Section of Bronchoscopy, Department of Pulmonary Medicine, Respiratory Institute, and Transplantation Center, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Machuzak
Section of Bronchoscopy, Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Cicenia
Section of Bronchoscopy, Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Umur Hatipoğlu
Director, COPD Center, Respiratory Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Pressure-volume loops while breathing at rest and during exercise in a healthy individual (A) and in a patient with chronic obstructive pulmonary disease (COPD) (B). Inspiratory capacity (maximum volume of breath that can be taken in after exhalation) increases in healthy people during exercise owing to a fall in lung volume at the end of exhalation. The volume loop during normal breathing is situated in the central linear portion of the pressure-volume relationship, which means that relatively small changes in pressure produce comparatively large changes in volume. In COPD, inspiratory capacity declines due to progressive air-trapping during exercise; thus, patients have to breathe at the upper and less compliant portion of the pressure-volume relationship. This means that increasingly higher pressures must be generated for any given breath, increasing the work of breathing.

    IC = inspiratory capacity; IRV = inspiratory reserve volume; P = pressure; RV = residual volume; TLC = total lung capacity; V = volume

    Used with the permission of the American Thoracic Society.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Valve therapy for bronchoscopic lung volume reduction involves implantation of 1-way valves to allow air flow and mucus clearance outward to central airways. The 1-way flow leads to selective de-aeration and collapse of treated areas, reducing hyperinflation and air trapping. Unlike lung volume reduction surgery, the procedure is performed unilaterally due to the inherent procedural risk of pneumothorax.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Specialized computed tomography software allows objective quantification of fissure integrity. The arrow indicates a complete fissure, and the arrowhead indicates incomplete fissure. Collateral ventilation is considered highly likely when the fissure is incomplete by > 20% across its span. This is a contraindication to valve therapy.

Tables

  • Figures
    • View popup
    TABLE 1

    Bronchoscopic approaches to lung volume reduction

    Valve therapy: Zephyr and Spiration
    Lung volume reduction coils: PneumRx10
    Airway bypass stents (abandoned due to lack of efficacy and high complication rate)11
    Bronchoscopic thermal vapor ablation (inducing scarring in the diseased airways leading to lung volume reduction)12
    Biologic or polymeric lung volume reduction: fibrin-thombin mixtures, glue, polymeric foam sealant (the AeriSeal System)13-16
    • View popup
    TABLE 2

    Randomized controlled trials of bronchoscopic lung volume reduction

    BELIEVER-HIFI19 2015 (N=50)STELVIO20 2015 (N=68)IMPACT21 2016 (N=93)TRANSFORM22 2017 (N=97)LIBERATE23 2018 (N=190)REACH24 2019 (N=107)EMPROVE25 2018 (N=172)
    DesignSingle-center 1:1; BLVR vs sham procedure over 3 monthsSingle-center 1:1;BLVR vs standard care over 6 monthsMulticenter 1:1; BLVR vs standard care over 3 monthsMulticenter 2:1; BLVR vs standard of care over 3 monthsMulticenter 2:1; BLVR vs standard care over 12 monthsMulticenter 2:1; BLVR vs standard care over 3 monthsMulticenter 2:1; BLVR vs standard care over 12 months
    Emphysema typeHeterogeneousaHeterogeneous, homogeneousHomogeneousbHeterogeneouscHeterogeneousdHeterogeneousdHeterogeneousc
    Valve systemZephyrZephyrZephyrZephyrZephyrSpirationSpiration
    Pulmonary function test criteriaFEV1 < 50%
    TLC > 100%
    RV > 150%
    FEV1 < 60%
    TLC > 100% RV > 150%
    FEV1 <
    15-45%
    TLC > 100%
    RV > 200%
    FEV1 < 15-45%
    TLC > 100%
    RV > 180%
    FEV1 < 15-45%
    TLC > 100%
    RV > 150%
    DLCO > 20%
    FEV1 < 45%
    TLC > 100%
    RV > 150%
    FEV1 < 45%
    TLC > 100%
    RV > 150%
    Collateral ventilation, fissure integrity assessmentHigh-resolution CTChartis systemChartis systemChartis systemChartis systemHigh-resolution CTHigh-resolution CT
    Clinical outcome, change from baseline
     FEV1, % of predicted8.720.913.720.717.113.512.1
     6-min walk distance (m)256022.636.212.927.16.9
     Reduction in RV (L)0.260.860.420.660.490.520.36
     Quality of life scoree8.617.38.67.27.57.69.5
     Pneumothorax occurrence, %8.617.627.92334.37.612.4
    • ↵a Defined as a National Emphysema Treatment Trial score of > 2 and a difference of > 1 emphysema score from ipsilateral lobes. Emphysema score ranges from 0-4; 0 represents absence of emphysema, and 1-4 represents quartiles of emphysematous lung involvement. For example, a score of 3 means 50% to 75% involvement with emphysema.

    • ↵b Defined as a < 15% difference in destruction score by quantitative high-resolution computed tomography (CT).

    • ↵c Defined as a > 10% difference in destruction score by quantitative high-resolution computed tomography.

    • ↵d Defined as a > 15% difference in destruction score by quantitative high-resolution computed tomography.

    • ↵e St. George Respiratory Questionnaire score.

    • DLCO = diffusing capacity for carbon monoxide; FEV1 = forced expiratory volume in 1 second; RV = residual volume; TLC = total lung capacity

    • View popup
    TABLE 3

    Selection criteria for valve therapy in emphysema

    Severe airflow obstruction:
    FEV1 between 15% and 45% of predicted
    Severe air trapping and hyperinflation:
    TLC > 100% and RV > 175% of predicted
    Severe emphysematous destruction in target lobe:
    > 50% involvement
    Absence of collateral ventilation between target lobe and neighboring lobe or lobes
    Adequate gas exchange:
    diffusion capacity > 20% of predicted, PaCO2 < 50 mm Hg, PaO2 > 45 mm Hg at baseline
    No history of frequent severe exacerbations:
    > 2 hospitalizations over the past year
    Absence of clinically significant sputum production: “significant” production, > 4 tablespoons per day
    No significant comorbidities:
    eg, cor pulmonale, ejection fraction < 45%, recent myocardial infarction
    No prior lung volume reduction surgery, lobectomy, lung transplant
    • FEV1 = forced expiratory volume in 1 second; PaCO2 = partial arterial pressure of carbon dioxide; PaO2 = partial arterial pressure of oxygen; RV = residual volume;

    • TLC = total lung capacity

    • Adapted from reference 23.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 87 (5)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 5
1 May 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bronchoscopic lung volume reduction with valves: What should the internist know?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bronchoscopic lung volume reduction with valves: What should the internist know?
Khaled Alshabani, Thomas R. Gildea, Michael Machuzak, Joseph Cicenia, Umur Hatipoğlu
Cleveland Clinic Journal of Medicine May 2020, 87 (5) 278-287; DOI: 10.3949/ccjm.87a.19083

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Bronchoscopic lung volume reduction with valves: What should the internist know?
Khaled Alshabani, Thomas R. Gildea, Michael Machuzak, Joseph Cicenia, Umur Hatipoğlu
Cleveland Clinic Journal of Medicine May 2020, 87 (5) 278-287; DOI: 10.3949/ccjm.87a.19083
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • LUNG CHANGES IN EMPHYSEMA
    • A BRIEF HISTORY OF LUNG VOLUME REDUCTION
    • THE NEED FOR NONSURGICAL OPTIONS
    • VALVE THERAPY
    • CLINICAL TRIALS OF VALVE THERAPY AFTER THE VENT STUDY
    • PATIENT SELECTION IS KEY
    • CONCLUSION AND FUTURE DIRECTIONS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Managing right ventricular failure in the setting of pulmonary embolism
  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Pulmonology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire